FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Investigation raises serious questions about the harm-benefit balance of Rexulti; the Decision may reverse efforts to reduce the use of antipsychotics in US care homes. During testing, the antipsychotic medication brexpiprazole (Rexulti) did not demonstrate a significant therapeutic effect and was

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

Not Everyone Agreed With FDA Approval of Antipsychotic Rexulti for

FDA's Shocking Approval: Rexulti Fast-Tracked Despite Deadly Risks

FDA's Fast-Track for Rexulti Raises Concerns

U.S. FDA Approved Drugs from 2015–June 2020: A Perspective

FDA's Fast-Track for Rexulti Raises Concerns

Pristiq: Side effects and what to do about them

FDA Law Blog

How the FDA approved an antipsychotic that failed to show a

Accelerated Change: Understanding the FDA's Expedited Pathways